Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3947 - Integrated population pharmacokinetic modelling of liposomal irinotecan in patients with various tumour types, including untreated metastatic pancreatic cancer (mPC)

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Pancreatic Adenocarcinoma

Presenters

Teresa Macarulla

Citation

Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247

Authors

T. Macarulla1, K. Brendel2, C.H. Lieu3, Z.A. Wainberg4, F. Dayyani5, B. Zhang6, B. Belanger7, Y. Moore6, A. Pedret-Dunn8, F. Maxwell9, A. Dean10

Author affiliations

  • 1 -, Vall d´Hebrón University Hospital and Vall d´Hebrón Institute of Oncology, 08035 - Barcelona/ES
  • 2 -, Ipsen, 91140 - Les Ulis/FR
  • 3 -, University of Colorado, 80045 - Aurora/US
  • 4 -, Ronald Reagan UCLA Medical Center, 90095 - Los Angeles/US
  • 5 -, University of California Irvine, 92697 - Orange/US
  • 6 -, Ipsen Bioscience, 02142 - Cambridge/US
  • 7 -, Ipsen Bioscience, Cambridge/US
  • 8 -, Ipsen Bioinnovation, OX14 4RY - abingdon/GB
  • 9 -, Ipsen Bioinnovation, OX14 4RY - Abingdon/GB
  • 10 -, St John of God Subiaco, Subiaco/AU

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3947

Background

Liposomal irinotecan (nal-IRI) is a liposomal formulation of irinotecan which prolongs circulation of irinotecan and its active metabolite SN-38. This analysis describes the population pharmacokinetics (PK) of nal-IRI in patients with various tumour types, including untreated mPC.

Methods

Plasma concentration data for total irinotecan (tIRI) and SN-38 from an open-label, phase 2 study of nal-IRI plus 5-fluorouracil/leucovorin and oxaliplatin in patients with untreated mPC (NCT02551991; N = 48) were pooled with data from six other nal-IRI studies (five phase 1/2, one phase 3) in various tumour types. Data from overall 440 patients were used in the population PK model for tIRI and SN-38 after nal-IRI administration. PK parameters were estimated with non-linear mixed effects modelling. The adequacy of the model was assessed based on the uncertainty of parameter estimates, and on advanced evaluation methods such as visual predictive check. Potential covariates such as patient demographics and genotype were investigated to examine inter-individual variability.

Results

tIRI is described by a two-compartment model with first-order elimination. SN-38 is formed directly by a first-order constant from the central compartment of nal-IRI or after using a transit compartment. In the pooled population (N = 440), clearance was 0.1 L/h and 150 L/h for tIRI and SN-38, respectively. Central and peripheral volumes of distributions for tIRI were 4 L and 0.4 L, respectively. Consistent with previous data, tIRI clearance was 80% higher in patients of Asian ethnicity (n = 154/440) than other populations. Increasing bilirubin levels were associated with lower SN-38 clearance, and tIRI and SN-38 clearances were 20% lower in females than males. The UGT1A128 7/7 homozygous genotype (6% of the study population) had no statistically significant impact on SN-38 clearance. Model evaluation was satisfactory for both tIRI and SN-38.

Conclusions

The PK of nal-IRI and SN-38 in patients with mPC is well described by the population model. The results suggest that UGT status has no impact on the PK of nal-IRI.

Clinical trial identification

Editorial acknowledgement

Oxford PharmaGenesis, Oxford, UK for providing editorial support, which was sponsored by Ipsen, Abingdon, UK.

Legal entity responsible for the study

Ipsen.

Funding

Ipsen.

Disclosure

T. Macarulla: Honoraria (institution): Shire Pharmaceuticals; Honoraria (institution): Roche; Honoraria (institution): Tesaro; Honoraria (institution): Baxter; Honoraria (institution), Travel / Accommodation / Expenses: Sanofi; Honoraria (institution): Celgene; Honoraria (institution): QED Therapeutics; Honoraria (institution): Genzyme Europe; Honoraria (institution): Baxalta; Honoraria (institution), Travel / Accommodation / Expenses: Bayer; Honoraria (institution): Incyte; Honoraria (institution): Genzyme; Travel / Accommodation / Expenses: Merck; Travel / Accommodation / Expenses: H3 Biomedicine. K. Brendel: Full / Part-time employment: Ipsen. Z.A. Wainberg: Advisory / Consultancy: Lilly; Advisory / Consultancy: Merck; Advisory / Consultancy: BMS; Advisory / Consultancy: Bayer; Advisory / Consultancy: Novartis; Advisory / Consultancy: Ipsen. F. Dayyani: Advisory / Consultancy: Array; Advisory / Consultancy, Speaker Bureau / Expert testimony: Eisai; Advisory / Consultancy, Speaker Bureau / Expert testimony: Genentech; Speaker Bureau / Expert testimony: Ipsen; Speaker Bureau / Expert testimony: Amgen; Speaker Bureau / Expert testimony: Sirtex. B. Zhang: Full / Part-time employment: Ipsen. B. Belanger: Full / Parttime employment: Ipsen. Y. Moore: Full / Part-time employment: Ipsen. A. Pedret-Dunn: Full / Parttime employment: Ipsen. F. Maxwell: Full / Part-time employment: Ipsen. A. Dean: Advisory / Consultancy, Non-paid: Shire; Advisory / Consultancy, Non-paid: Specialised Therapeutics Australia; Travel / Accommodation / Expenses, Grant: Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.